Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 332 publications
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.
Journal: The Journal of dermatological treatment
Published: June 11, 2026
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
Journal: The Journal of dermatological treatment
Published: June 01, 2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.
Journal: JAMA dermatology
Published: May 15, 2026
GRAPPA 2025 Collaborative Research Network Meeting: Difficult-to-Treat Psoriatic Arthritis and Future Strategies for Curing Psoriasis.
Journal: The Journal of rheumatology
Published: May 15, 2026
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review.
Journal: JAMA dermatology
Published: April 29, 2026
Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials.
Journal: The Journal of dermatology
Published: April 28, 2026
Real-World Evidence That As-Needed Dosing with Bimekizumab in Patients with Psoriasis Is Safe and Effective over Time.
Journal: Journal of personalized medicine
Published: March 25, 2026
Cutaneous adipose tissue carries a strong inflammatory signature in patients with psoriasis.
Journal: JCI insight
Published: March 03, 2026
Comparison of treatment with GP2017 (an adalimumab biosimilar) and reference adalimumab in people with plaque psoriasis: a plain language summary of the ADACCESS trial.
Journal: Immunotherapy
Published: February 19, 2026
Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review.
Journal: Dermatology and therapy
Published: February 17, 2026
Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study.
Journal: Expert opinion on investigational drugs
Published: February 10, 2026
Last Updated: 09/26/2026